Medifast, Inc. (MED)

Over the past six months, Medifast's stock price has been impacted by its financial performance and strategic response to market changes, experiencing a decline of 12.11% over the last six months and 26.47% over the past year. In Q3 2025, Medifast reported revenue of $89.4 million, a 36.2% year-over-year decrease, and a net loss of $2.3 million (-$0.21 per share). Medifast is strategically transforming from a weight-loss company to a leader in metabolic health, with a new product line planned for launch in 2026. The company provided Q4 2025 guidance projecting revenue between $65 million and $80 million and an estimated loss per share between $0.70 and $1.25. As of early February 2026, Medifast's stock has been trading near its 52-week low of $10.12, with analysts giving it a consensus "hold" rating and a median target price of $23.30.

While the provided information does not explicitly detail traditional seasonal demand patterns for Medifast's products and services, it strongly indicates that demand has been significantly impacted by broader market shifts rather than typical seasonality in the past year. The primary factor influencing demand has been the disruptive impact of the rising popularity of GLP-1 medications and a general slowdown in consumer spending. Medifast's strategic initiatives, including the launch of OPTAVIA ASCEND, are aimed at adapting to these evolving market demands and are expected to show positive results later in 2025 and into 2026.

Medifast, Inc. is a health and wellness company known for its science-backed, coach-guided lifestyle system, operating in the weight management industry. The company is strategically repositioning from a weight-loss company to a leader in promoting metabolic health, with its core offering being the OPTAVIA brand, which provides a lifestyle solution focused on developing healthy habits through a community of independent coaches. Medifast's major products under the OPTAVIA brand include a variety of "Fuelings" and the company has also introduced OPTAVIA ASCEND, a new product line featuring high-protein, fiber-rich mini meals and daily nutrient packs. Medifast distributes its products and programs through various channels, including its websites, national call centers, a network of physicians, medically supervised Medifast Weight Control Centers, and its direct-selling division, OPTAVIA, which utilizes health coaches.

Medifast, Inc. is headquartered in Baltimore, Maryland, United States, and has a significant presence in the United States, where it is recognized as a market leader by revenue in the weight management industry. While Medifast aims to lead a "global movement" in health and wellness, specific details regarding extensive international operations or a detailed geographic footprint beyond its strong U.S. market presence are not explicitly detailed in the provided information.

In the past year, Medifast's brand reputation has been shaped by its response to the evolving weight management market, particularly the rise of GLP-1 medications. Medifast is transforming its brand identity from solely a weight-loss company to a leader in promoting metabolic health. Recognizing the disruptive impact of GLP-1 medications, Medifast has launched OPTAVIA ASCEND, a new product line and nutrition plans specifically designed for individuals using GLP-1 medications and those seeking weight maintenance. A key challenge impacting Medifast's reputation and business performance has been the year-over-year decline in active OPTAVIA coaches and client acquisition. In December 2023, Medifast announced a partnership with LifeMD to offer a clinically supported weight management program. Despite market challenges, Medifast continues to emphasize its science-backed, coach-guided lifestyle system and clinically proven plans.

Medifast, Inc. has a significant institutional ownership presence, with 265 institutional owners and shareholders holding a total of 10,271,946 shares, accounting for approximately 84.61% of the shares outstanding. Major institutional owners include BlackRock, Inc., Renaissance Technologies Llc, and Vanguard Group Inc. As of late 2025, mutual funds and ETFs held 35.45% of shares outstanding, while other institutional investors held 54.92%, and public companies and retail investors held 9.63% of the shares.